Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Context Therapeutics Inc.NASDAQ: CNTX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$9.34M, compared with -$5.53M a year earlier. Trailing-twelve-month operating income was -$43.52M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -32.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.34M+32.3% QoQ
- Last fiscal yearDec 2025
- -$39.7M-32.7% YoY
- LTMMar 2026
- -$43.52M-37.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -69.0% | +100.0% | +169.0 pp |
| 1 year | -32.7% | +100.0% | +132.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (39.7M) USD
- Year-over-year change
- -32.7%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.7M) | -32.7% |
| FY2024 | 2024-12-31 | (29.92M) | -19.3% |
| FY2023 | 2023-12-31 | (25.07M) | -63.0% |
| FY2022 | 2022-12-31 | (15.38M) | -46.1% |
| FY2021 | 2021-12-31 | (10.53M) | — |
Operating Income vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.6% is the 9th highest of 11, against a peer median of +18.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$14.25M USD | +0.5% | — | — | |
| LTM Mar 2026 | -$20.82M USD | +25.5% | — | 15535.1% | |
| LTM Mar 2026 | -€42.37M EUR | +20.8% | — | 144445.0% | |
| LTM Mar 2026 | -$43.52M USD | -37.6% | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$47.63M USD | +33.8% | — | — |
| LTM Mar 2026 | -$47.74M USD | +16.3% | — | 670.2% | |
| LTM Mar 2026 | -$52.66M USD | +29.7% | — | 5266.4% | |
IMAImageneBio Inc | LTM Mar 2026 | -$55.93M USD | -8.5% | — | — |
| FY2025 | -$58.07M USD | -158.7% | — | 90740.6% | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$122.7M USD | -94.3% | — | — |
| Peer median (excluding CNTX) | — | +18.6% | — | 10400.7% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| Weighted Avg Shares | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
| Weighted Avg Shares (Diluted) | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.